Attorney Docket No.: 6413.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

PECHIVED TAX CENTER

Serial No.: 10/614,233

Group Art Unit: 1614

JAN 1 8 2005

Filed: July 7, 2003

Examiner: Henley III, Raymond J.

For: Pharmaceutical Use of Boronic Acids and Esters Thereof

CERTIFICATE OF FACSIMILE TRANSMISSION 703-872-9306

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment (19 pages)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Raymond J. Henley III, fax number (703) 872-9306.

Respectfully submitted,

Date: January 18, 2005

Csaba Attila Szakolczai Novo Nordisk® Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800

Attorney Docket No. 6413.204-US Ebdrup et al.

Scrial No. 10/614.233 Filed July 7, 2003

Attorney Docket No.: 6413.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

Confirmation No.: 6226

Application No.: 10/614,233

Group Art Unit: 1614

JAN 1 8 2005

Filed: July 7, 2003

Examiner: Henley III, Raymond J.

For: Pharmaceutical Use of Boronic Acids and Esters Thereof

AMENDMENT/RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This amendment is timely submitted in response to the final Office Action on the merits mailed October 18, 2004, having a shortened statutory period for reply set to expire January 18, 2005, subject to extensions of time under the provisions of 37 CFR §1.136(a).

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this Amendment, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk, Inc., for any such required fee.

The examiner states in the Office Action Summary that claims numbered 1-5 and 7-66 are pending in the application; claims numbered 1-3, 8-30, 33, 34 and 36-61 are allowed; claims numbered 4, 5, 7, 31, 32, 35 and 62-66 are rejected; and claims numbered 4 and 7 are objected to.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application.

Claims numbered 1, 4, 7, 9 and 31 have been amended herein.